INSTEM acquired by ARCHIMED
Context
ARCHIMED has successfully completed the take-private acquisition of Instem, delisting the company from the London Stock Exchange (AIM). The transaction was driven by the need to liberate Instem from the short-term pressures of public reporting, allowing for more aggressive investment in long-term R&D. The strategic roadmap focuses on accelerating the adoption of "in silico" methods—using data and AI to model drug effects—which reduces the industry's reliance on animal testing and speeds up time-to-market. ARCHIMED intends to use Instem as a consolidation platform in the fragmented pre-clinical software market, leveraging its "MedTalents" network to source add-on acquisitions and drive international expansion.
INSTEM, which reported an EBITDA margin of [members only] in 2022, is valued in this transaction at an EV/EBITDA multiple of 15x–25x, representing a premium to the average currently observed in the TMT (Tech, Media, Telecom) sector (14.6x).
-> Deep-dive in TMT (Tech, Media, Telecom) market trends
Target
Headquartered in Staffordshire, Instem is a leading provider of IT solutions for the global life sciences market. Its software suite is critical for the early stages of drug development (pre-clinical), helping pharmaceutical companies manage data, streamline workflows, and ensure regulatory compliance (specifically with the "SEND" standard mandated by the FDA). The company is also a pioneer in "in silico" simulation, using computer modeling to predict the toxicity and carcinogenicity of drugs before they are tested on animals or humans.
Ent. Value
£100–350M
Equity Value
[members only]
Multiples
EV / Revenue
2x–6x
EV / EBITDA
15x–25x
EV / EBIT
Above 20x
Historical Financials (GBP)
Similar deals in Software
Similar deals in Software
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 12/2023 | SEPTEO | SEQUOIASOFT | FRANCE | Travel & Hospitality |
| 12/2023 | HG CAPITAL | VISMA GROUP | NORWAY | ERP, HR & Finance |
| 11/2023 | DEVOLVER DIGITAL | SYSTEM ERA SOFTWORKS | UNITED STATES | Gaming & Consumer Apps |
| 11/2023 | KEYSIGHT TECHNOLOGIES | ESI GROUP | FRANCE | Engineering & Design Software |
| 11/2023 | 21 INVEST | CONEX | FRANCE | Industry-Specific Software |
| 11/2023 | OPTIMIZERX | MEDICX HEALTH | UNITED STATES | AdTech |
| 11/2023 | PSG EQUITY | DIAPASON | FRANCE | ERP, HR & Finance |
| 11/2023 | OCEANSOUND PARTNERS | MESSAGE BROADCAST | UNITED STATES | MarTech |
| 10/2023 | CAPZA | TRAVELSOFT | FRANCE | Travel & Hospitality |
| 10/2023 | SANDVIK | ESCO | GERMANY | Supply Chain & Ops |
Other operations with ARCHIMED
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 09/2016 | ARCHIMED | POLYPLUS | FRANCE | R&D Biotech |
REFERENCES
Valuation range: EV £100–350M
Revenue range: £50–100M
EBITDA range: £5–25M
EV/Revenue range: 2x - 6x
EV/EBITDA range: 15x - 25x
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of INSTEM by ARCHIMED are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Press release: view release
Target: instem
Acquirer: archimed